BioPharmSignal logoBioPharmSignal

Biotech News

AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)

AN2 Therapeutics (ANTX)AN2 TherapeuticsClinical readout

Novel boron-based oral ENPP1 inhibitor advances into development Oral profile tailored specifically for HPP with potent and specific ENPP1 inhibition, efficacy in proof-of-concept animal models, and favorable pharmacokinetic properties Phase 1 study planned for 2H/2027 MENLO PARK, Calif.

Related news

ANTXAN2 Therapeutics2026-10-21 11:00 EST

AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms

ANTXAN2 Therapeutics2026-06-04 11:00 EST

AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease

SCYXSCYNEXIS2026-10-22 12:00 EST

SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases

SPROSpero Therapeutics2026-07-14 11:00 EST

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

SPROSpero Therapeutics2026-07-27 13:00 EST

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

ASMBAssembly Biosciences2026-05-22 11:00 EST

Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases

IMNNImunon2026-09-22 12:05 EST

IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review

ENTAEnanta Pharmaceuticals2026-06-18 11:00 EST

Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)

ASMBAssembly Biosciences2026-10-29 20:00 EST

Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus

SCYXSCYNEXIS2026-10-06 11:30 EST

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

View all latest news

AN2 Therapeutics

Boron-Based Drug Development AN2 Therapeutics develops small-molecule medicines derived from its boron chemistry expertise, with programs spanning hematology, infectious disease, and oncology. Epetraborole in Polycythemia Vera AN2 is preparing the EBO-PV-201 Phase 2 proof-of-concept study of epetraborole in phlebotomy-dependent...

Recent company news

ANTXAN2 Therapeutics2026-11-04 21:00 EST

AN2 Therapeutics to Present at Jefferies Global Healthcare Conference in London

ANTXAN2 Therapeutics2026-11-04 12:00 EST

AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)

ANTXAN2 Therapeutics2026-11-02 12:00 EST

AN2 Therapeutics Receives U.S. FDA IND Clearance to Proceed with Planned Phase 2 Global Study of Oral Epetraborole in Polycythemia Vera

ANTXAN2 Therapeutics2026-10-23 21:00 EST

AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)

ANTXAN2 Therapeutics2026-10-21 11:00 EST

AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms

Stock data

Close
3.96 USD
Market cap
146.59M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States